This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sequenom Mania Fueled By Fuzzy Math: BioBuzz

SAN DIEGO ( TheStreet) -- In upgrading Sequenom (SQNM) to a "buy" from "hold" Tuesday morning, the Cantor Fitzgerald analyst uses some very fluffy financial assumptions and questionable accounting.

It looks to me like Pamela Bassett came up with her new, super-bullish $16 price target for Sequenom first, then worked backwards in her financial model to justify it.

The income statement attached to her note Tuesday projects Sequenom total revenue of $49.3 million this year, zooming to $279.5 million in 2011.

Wow! It would be impressive, indeed, if Sequenom somehow managed to grow total revenue by more than 460% in a year, especially since the company's most important revenue generating project -- a blood-based fetal gene test for Down's syndrome -- doesn't even exist at this point because an earlier, much-hyped version blew up last year.

More recently, Sequenom announced plans to launch a gene-based test to determine fetal sex. But expectant parents have been using ultrasound tests to find out whether they're having a girl or a boy for decades. It's highly unlikely that an expensive and unreimbursed gene-based test is ever going to catch on commercially.

Bassett doesn't offer much detail to justify her lofty revenue projections, except to say, "Sequenom's commitment to launching its next-gen MassARRAY platform will be a key driver of long-term growth."

What she does do, however, is use her $279.5 million in 2011 revenue to project Sequenom earnings of 63 cents a share in 2011. Those 2011 earnings come off a basic share count that grows less than 1% from 2010 levels, despite the fact that Sequenom's new management team has already stated the company needs to raise money.

I'm not naive enough to believe that Bassett's fuzzy math and ridiculous projections mean anything at this point. She's just feeding the stock's momentum-fueled frenzy. Sequenom shares are up 22% to $8.43 Tuesday; the stock has doubled in price so far this year.

With a valuation now topping $500 million, investors buying the stock at these levels better hope Sequenom can develop a blood-based fetal gene test for Downs Syndrome.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
SQNM $4.59 0.00%
AAPL $128.95 0.00%
FB $78.99 0.00%
GOOG $537.90 0.00%
TSLA $226.03 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs